Release Date: September 12, 2025
Expiration Date: September 12, 2026
Activity Overview
Prostate cancer continues to pose substantial clinical challenges, with increasing incidence and mortality rates in the United States. Radioligand therapy (RLT) directed at prostate-specific membrane antigen (PSMA) and advanced imaging technologies have transformed the diagnosis and treatment of metastatic prostate cancer, but knowledge gaps persist regarding optimal use, patient selection, sequencing, and integration into multidisciplinary care. Additionally, disparities in access and implementation across care settings underscore the urgent need for clinician education. To address these unmet needs, PER® has developed this online activity that features expert video interviews.
Target Audience
This activity is directed toward medical oncologists, urologists, nuclear medicine physicians, and radiation oncologists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss key elements and guidelines for PSMA PET-CT interpretation in clinical practice to support accurate clinical decision-making
- Assess the mechanistic and clinical rationale supporting the role of PSMA-targeting radioligand therapy in the management of patients with metastatic prostate cancer
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here